Amy M. Scurlock
Professor
Also affiliated: University of North Carolina at Chapel Hill (2020); National Institutes of Health (2004–2024); Arkansas Children's Hospital (2002–2026); Harvard University (2026); California State University, Fullerton (2011); Johns Hopkins University (2024); University of Tennessee Health Science Center (2011); Duke University (2004); University of Arkansas Medical Center (2006–2026); Johns Hopkins Medicine (2024); Duke Medical Center (2004); National Institute of Allergy and Infectious Diseases (2024); Johns Hopkins Hospital (2024); National Institutes of Health Clinical Center (2004); Arkansas Children's Research Institute (2005–2026); Mass General Brigham (2026); Icahn School of Medicine at Mount Sinai (2024)
Peds Pediatrics, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Amy M. Scurlock's research focuses on the evaluation of mucosal immune responses in models of food allergy and eosinophilic gastrointestinal disorders. She has a clinical interest in allergic and immunologic diseases, including food allergy, atopic dermatitis, eosinophilic esophagitis, and primary immunodeficiency. Dr. Scurlock also investigates newborn screening and long-term follow-up for infants with severe combined immunodeficiency (SCID) and T-cell lymphopenia.
Dr. Scurlock is actively involved in clinical trials, including investigator-initiated, industry-sponsored, and federal and foundation-sponsored studies. She participates in the Food Allergy Research and Education (FARE) Clinical Network and FARE Neighborhoods Program and serves on the Steering Committee for the NIAID Consortium of Food Allergy Research (CoFAR). Her work also extends to promoting food security and improving access to safe, healthy foods through cross-disciplinary collaborations.
Her academic contributions include a high-impact researcher designation, with an h-index of 36, 162 total publications, and over 7,249 citations. Dr. Scurlock collaborates with researchers such as Stacie M. Jones, Emily Seminara, Akilah A. Jefferson, and Dieu Doan, all from the University of Arkansas for Medical Sciences.
Research Overview
Amy M. Scurlock, M.D. is an Associate Professor of Pediatrics at the University of Arkansas for Medical Sciences and Arkansas Children's Hospital. Dr. Scurlock is also a researcher at Arkansas Children's Hospital Research Institute. Dr. Scurlock received her M.D. in 1998 from the University of Arkansas for Medical Sciences. She completed a residency in Pediatrics at UAMS/ACH in 2001 and served as Chief Resident until 2002. She completed her Allergy-Immunology Fellowship Training at Duke University Medical Center in Durham North Carolina in 2004. Dr. Scurlock joined the UAMS faculty in August 2004 as a member of the Division of Pediatric Allergy/Immunology within the Department of Pediatrics. Dr. Scurlock's clinical interests include allergic and immunologic diseases such as food allergy, atopic dermatitis, eosinophilic esophagitis and primary immunodeficiency. She also has interest in newborn screening and long-term follow-up for infants with SCID and T-cell lymphopenia. Her research interests are focused on evaluation of mucosal immune responses in models of food allergy and eosinophilic gastrointestinal disorders. Dr. Scurlock is a member of the American Academy of Allergy Asthma and Immunology (AAAAI), Society for Mucosal Immunology, Society for Pediatric Research, Clinical Immunology Society, and American Academy of Pediatrics. She is board certified in both Pediatrics and Allergy-Immunology. Some of the UAMS College of Medicine faculty members provide pediatric patient care at Arkansas Children's Hospital. In addition, a wide range of pediatric services are provided in more than 35 subspecialties around Arkansas in locations such as the Schmieding Developmental Center in Springdale and the James L. Dennis Developmental Center in Little Rock. To make an appointment at Arkansas Children's Hospital, please call 501-364-4000.
Metrics
- h-index: 39
- Publications: 177
- Citations: 7,693
Positions
-
Professor 2004–presentUniversity of Arkansas for Medical Sciences Peds Pediatrics, College of Medicine Institutional directory
Selected Publications
-
Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy (2026)
-
Early-life peanut oral immunotherapy associated with long-term ingestion and immunologic changes (2026)
-
Clinical conundrum: solving the mystery (2026)
-
Implementation of early peanut introduction among providers in a southern US state (2026)
-
Management of Gastrointestinal Symptoms During Oral Immunotherapy: Guidance from OUtMATCH Investigators (2026)
-
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies (2025)
-
Introduction of allergenic foods after treatment with omalizumab (2025)
-
Introduction Of Allergenic Foods After Treatment With Omalizumab (2025)
-
Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes (2025)
-
Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent (2024)
-
Food Insecurity and Health Inequities in Food Allergy (2024)
-
Long-term walnut oral immunotherapy induces shifts in serum antibody binding patterns to walnut and cross-reactive tree nuts (2024)
-
Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial (2024)
-
Survey of Arkansas Pediatric Providers on the Application of the NIH/NIAID Addendum Guidelines for the Prevention of Peanut Allergy in the United States (2024)
-
Food insecurity and allergic diseases: A call to collective action (2023)
Grants & Funding
As listed on this researcher's institutional profile.
- FARE Network UAMS ACHRI Flow Through Principal Investigator
- Immunoregulatory Networks in Chlamydia Genital Tract Infection NIH Principal Investigator
Collaboration Network
Top Collaborators
- Clinical efficacy and immune regulation with peanut oral immunotherapy
- Oral Immunotherapy for Treatment of Egg Allergy in Children
- A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Egg oral immunotherapy in nonanaphylactic children with egg allergy
Showing 5 of 68 shared publications
- Clinical efficacy and immune regulation with peanut oral immunotherapy
- Oral Immunotherapy for Treatment of Egg Allergy in Children
- A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Egg oral immunotherapy in nonanaphylactic children with egg allergy
Showing 5 of 41 shared publications
- Clinical efficacy and immune regulation with peanut oral immunotherapy
- A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Adverse reactions during peanut oral immunotherapy home dosing
- Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy
Showing 5 of 35 shared publications
- Clinical efficacy and immune regulation with peanut oral immunotherapy
- Oral Immunotherapy for Treatment of Egg Allergy in Children
- A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial
Showing 5 of 27 shared publications
- Clinical efficacy and immune regulation with peanut oral immunotherapy
- A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Egg oral immunotherapy in nonanaphylactic children with egg allergy
- Safety of a peanut oral immunotherapy protocol in children with peanut allergy
Showing 5 of 23 shared publications
- Oral Immunotherapy for Treatment of Egg Allergy in Children
- Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial
- Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial
- Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy
- Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges
Showing 5 of 16 shared publications
- Oral Immunotherapy for Treatment of Egg Allergy in Children
- Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial
- Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens
- Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial
- Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy
Showing 5 of 15 shared publications
- A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Safety of a peanut oral immunotherapy protocol in children with peanut allergy
- Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison
- Early and Persistent Gastrointestinal Side Effects Predict Withdrawal from Peanut Oral Immunotherapy (OIT)
Showing 5 of 13 shared publications
- Evidence of pathway‐specific basophil anergy induced by peanut oral immunotherapy in peanut‐allergic children
- Oral Immunotherapy (OIT) Induces Clinical Tolerance in Peanut-Allergic Children
- Peanut Oral Immunotherapy (OIT) Induces Immunologic Changes Supporting the Development of Tolerance
- Oral Desensitization and Induction of Tolerance in Peanut-Allergic Children
- Double-Blind, Placebo-Controlled (DBPC) Trial of Oral Immunotherapy (OIT) in Peanut Allergic Children
Showing 5 of 12 shared publications
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges
- Impact of food allergy on food insecurity and health literacy in a tertiary care pediatric allergy population
- Pneumococcal Meningitis in a Patient with Irak-4 Deficiency: A Case of Failed Prophylactic Therapy
- Pneumococcal meningitis in a patient with IL-1 receptor–associated kinase-4 deficiency: A case of failed prophylaxis
Showing 5 of 12 shared publications
- Oral Immunotherapy for Treatment of Egg Allergy in Children
- Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial
- Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial
- Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy
- Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy
Showing 5 of 12 shared publications
- Clinical efficacy and immune regulation with peanut oral immunotherapy
- A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
- Evidence of pathway‐specific basophil anergy induced by peanut oral immunotherapy in peanut‐allergic children
- Peanut Oral Immunotherapy (OIT) Induces Immunologic Changes Supporting the Development of Tolerance
- Double-Blind, Placebo-Controlled (DBPC) Trial of Oral Immunotherapy (OIT) in Peanut Allergic Children
Showing 5 of 11 shared publications
- Oral Immunotherapy for Treatment of Egg Allergy in Children
- Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial
- Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial
- Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy
- Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy
Showing 5 of 10 shared publications
- Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison
- Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
Showing 5 of 10 shared publications
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
- Egg oral immunotherapy in nonanaphylactic children with egg allergy
- Impact of food allergy on food insecurity and health literacy in a tertiary care pediatric allergy population
- Oral Desensitization and Induction of Tolerance in Peanut-Allergic Children
- Anaphylaxis after ingestion of gummy bears
Showing 5 of 9 shared publications
Similar Researchers
Based on overlapping research topics